Key reimbursement alerts for office-administered drugs — C-Code, J-Code, NDC, and NCCN alerts plus pricing updates, sent on behalf of pharma manufacturers.
Effective January 1, 2024 EFFECTIVE JANUARY 1, 2024 xx NEW J-Code: J2508 xx Elfabrio is indicated for the treatment of adults with confirmed Fabry disease. Please see Important Safety Information below and Full Prescribing Information . xx New J-Code: J0127 x Lamzede is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. Please see Important Safety Information below and Full Prescribing Information . HCPCS Code Information Drug Elfabrio Lamzede J-Code J2508 J0217 Descriptor Injection, pegunigalsidase alfa-iwxj, 1 mg Injection, velmanase alfa-tycv, 1 mg HCPCS Code Dosage 1 MG 1 MG NDC Code Information Drug Elfabrio Lamzede Package Description One single-dose vial in a carton Five single-dose vials in a carton Ten single-dose vials in a carton One 10 mg single-dose vial in a carton NDC Code 10122-0160-02 10122-0160-05 10122-0160-10 10122-0180-02 WAC Per Package $4,135.11 $20,675.55 $41,351.10 $4,000.00 WAC Per…
The Comparative Report puts ASP, the Medicare payment limit, WAC and AWP for up to
15 drugs on one timeline. Ten-plus years of monthly history, per HCPCS unit.
Four benchmarks plus the ASP/WAC ratio on the same axis
Prebuilt biosimilar, therapeutic-area and mechanism groups
Index to 100 to compare a $7 drug against a $90 one
Sortable table, reference multiples, saved reports, PDF export